5-hydroxytryptamine2A receptor inverse agonists as antipsychotics - Test2 - elhamkhani - TriplyDB

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

http://www.wikidata.org/entity/Q28216479

about

sameAs

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model Role of the serotonin 5-HT(2A) receptor in learning Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning.Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection Animal Models of Psychosis: Current State and Future Directions.Molecular targets for treating cognitive dysfunction in schizophrenia.Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement.Chemical genomics: massively parallel technologies for rapid lead identification and target validation.Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of Akt Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction.Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthood Serotonin receptors and heart valve disease--it was meant 2B.Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists.Locomotion after spinal cord injury depends on constitutive activity in serotonin receptors Functional enhancement of AT1R potency in the presence of the TPαR is revealed by a comprehensive 7TM receptor co-expression screen.Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity.Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission Role of 5-HT2A receptor antagonists in the treatment of insomnia.Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.Integrated approaches to understanding antipsychotic drug action at GPCRs.On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy.Atypical antipsychotics and inverse agonism at 5-HT2 receptors.Signalling profile differences: paliperidone versus risperidone.Endogenous monoamine receptor activation is essential for enabling persistent sodium currents and repetitive firing in rat spinal motoneurons.Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interaction Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity

P2860

Q24646533-FDFCDE45-A82F-4CCC-A931-F7FAB9B7325B Q24685023-74F38CFA-4B43-4688-93B3-3319021D8C1A Q26745506-3F050473-38F7-4C78-868C-813E93A134F8 Q30365347-8124135D-EDF5-4A44-AC27-E6B45AE821FD Q30386608-D77F3417-1EC2-45E4-B654-CFF6D4D1931A Q30410153-634B3826-8A81-4A39-9810-C69142924D92 Q30491310-F2329CA2-FE6B-4964-A8A9-9016DFA2F13F Q30493133-24F11388-ADD3-48AA-912A-0630BE9DC485 Q30559794-26F8788F-D28B-446B-AD7C-337413988971 Q33383932-4751A5D2-709E-4C98-9B1A-B43D5E308F67 Q33764262-5C8CCED8-1764-41E5-AC92-D7D8D3E41B12 Q33874819-E8ABB317-CB18-4E30-9789-0FAF3F256C16 Q34053684-0DD316CF-819A-4504-935D-FD0977BCB286 Q34173511-107E0316-CD90-448D-8608-BCB8A3B00C02 Q34236107-20B30D6F-A0C7-42A1-968D-3FBDB4C223B8 Q34396223-0D5ECE83-784A-49DC-BD49-44180B4B566C Q34430446-D7AF6541-AA42-4E8F-BB10-01E0E4FBC85B Q34630128-E4D44E8C-807F-43E2-A826-313B7BAE306A Q34686451-77E1BC4D-4371-4C0B-95E0-DF4D2559163A Q36524716-286A1C9D-4E1B-4977-AC95-AFC901FB7B25 Q36534965-106A4571-90EB-4FA8-817F-42B7B12D0472 Q37416428-1D0275D4-F6EA-42A8-8D56-99C4C15A60C4 Q37949586-37FA19B6-FDB2-41CA-B2BE-AF90C6A34D71 Q38101551-01021173-7C2C-4856-9A94-8C8FA2D043F2 Q38167630-7E1E8F33-9CA5-4B94-8989-C5EF053CE106 Q38200335-38379E5E-F03C-480C-8ECB-6BC555CA9A25 Q38200546-94529734-9B8A-41BA-80E9-84FE831B2BDD Q39004795-F64FB14F-0F9A-4A1B-BFF5-D59A1456853A Q41250110-4A57DC07-46FA-451E-A677-A0F88E5FA375 Q41906281-6F857FF9-7843-4EFF-80CC-8F4FB9CDBDF2 Q47148816-28DF4CA1-7C03-49F6-A8B1-D6170FC02501 Q58695932-1F311E00-8C03-41A0-87F1-7A48202F8F63 Q58798205-FD48A0C5-245D-48F1-BA90-39E7D67F8325

P2860

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

http://www.wikidata.org/entity/Q28216479

description

2001 nî lūn-bûn

@nan

2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

@ast

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

@en

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

@nl

type

label

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

@ast

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

@en

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

@nl

prefLabel

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

@ast

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

@en

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

@nl

P1433

Q28216479-48821CD5-B44C-422D-8F4C-0A4B076B1AB6

P1476

Q28216479-DFB9C559-469B-4F3B-9FD8-4E24F9D6F8FD

P2093

Q28216479-049555AD-2BE6-45BA-9832-4C2FBD97903B

Q28216479-05B93DA4-EC31-4A4B-A810-06D22A8B7EB3

Q28216479-1621C2F3-FE2A-4380-A8D9-6E4CC2FAD805

Q28216479-16E2F65D-AF3A-47C4-BB23-926310F7F49A

Q28216479-1FA5A37C-D1D2-4480-B096-7246C28E27A0

Q28216479-209E1844-431C-4399-B816-55C3363A080D

Q28216479-3A5EAE9E-4A0B-49CF-9F71-DDCB4592263B

Q28216479-3B0783A1-807C-4CCD-B4CE-E8F14D03DF63

Q28216479-67C3A841-A955-48CD-B0FC-DE156ECB4839

Q28216479-6D6DBADA-7411-45DC-B8A3-FFAE83C097B6

P304

Q28216479-869E79A2-3092-48DD-A04B-FA2993130A30

P31

Q28216479-68D1E49A-B008-443A-B7BD-72E52D2422AE

P3181

Q28216479-6988AC97-F6AC-4BD1-8F7A-DE01C4E66AEC

P407

Q28216479-FCDDD576-6C8E-43F4-8DF1-CF120A592493

P433

Q28216479-AE4BF694-1E4C-43A4-8E3D-96BCC0FB73A7

P478

Q28216479-55C6608E-123C-44B0-A50B-20C03AAE5114

P577

Q28216479-39BD14AA-1FFF-4BDE-9419-F2F2F7312CE2

P698

Q28216479-86939828-2F94-4CC4-A924-B99E5D6C01BB

P3181

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

@en

P2093

Andersson CM

http://www.w3.org/2001/XMLSchema#string

Brann MR

http://www.w3.org/2001/XMLSchema#string

Burstein ES

http://www.w3.org/2001/XMLSchema#string

Croston GE

http://www.w3.org/2001/XMLSchema#string

Currier EA

http://www.w3.org/2001/XMLSchema#string

Donohue E

http://www.w3.org/2001/XMLSchema#string

Geyer MA

http://www.w3.org/2001/XMLSchema#string

Gibson DF

http://www.w3.org/2001/XMLSchema#string

Hacksell U

http://www.w3.org/2001/XMLSchema#string

Hansen HC

http://www.w3.org/2001/XMLSchema#string

P304

268-276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4704825

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

299

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11561089

http://www.w3.org/2001/XMLSchema#string